Who Paid My Doc
John Osborne
Cardiovascular Disease Grapevine, TX Medical Doctor
NPI 1114929718 CMS profile 186653
3801 William D Tate Ave Ste 850, Grapevine, TX 76051
General payments
$1,328,823
Research payments
$28,490
Ownership & investment interest
$0
Through program year 2025, John Osborne of Grapevine, TX is reported in the CMS Open Payments database as having received $1,328,823 across 1,109 general payments and $28,490 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 99th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
12 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $334,998 | 185 | |
| 2025 | Research | $3,919 | 3 | |
| 2024 | General | $217,024 | 170 | |
| 2024 | Research | $11,766 | 3 | |
| 2023 | General | $163,245 | 137 | |
| 2023 | Research | $10,263 | 5 | |
| 2022 | General | $193,453 | 145 | |
| 2022 | Research | $1,425 | 1 | |
| 2021 | General | $120,536 | 116 | |
| 2020 | General | $89,344 | 112 | |
| 2019 | General | $210,223 | 244 | |
| 2019 | Research | $1,117 | 1 |
Beside peers
- John Osborne
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to John Osborne were reported at $334,998. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | John Osborne | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $210,223 | $450 | $127–$1,392 | $163 |
| 2020 | $89,344 | $242 | $77–$751 | $114 |
| 2021 | $120,536 | $335 | $101–$1,037 | $132 |
| 2022 | $193,453 | $395 | $121–$1,211 | $149 |
| 2023 | $163,245 | $443 | $136–$1,283 | $160 |
| 2024 | $217,024 | $450 | $136–$1,323 | $164 |
| 2025 | $334,998 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 24 drugsPart D claims
609
Drug cost
$275,897
Branded share of claims
44.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 47 | $63,762 | |
| Ozempic Semaglutide | Brand | 41 | $48,492 | |
| Mounjaro Tirzepatide | Brand | 37 | $40,877 | |
| Jardiance Empagliflozin | Brand | 56 | $39,184 | |
| Entresto Sacubitril/Valsartan | Brand | 22 | $22,755 | |
| Nexlizet Bempedoic Acid/Ezetimibe | Brand | 23 | $21,240 | |
| Vascepa Icosapent Ethyl | Brand | 19 | $14,089 | |
| Repatha Sureclick Evolocumab | Brand | 17 | $13,445 | |
| Icosapent Ethyl | Generic | 23 | $5,339 | |
| Flecainide Acetate | Generic | 12 | $1,776 |
The 10 drugs with the highest cost, of 24 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 15 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| JARDIANCE |
|
$62,964 | 56 | — |
| Vascepa |
|
$42,716 | 19 | — |
| Wegovy |
|
$18,022 | — | — |
| KISQALI |
|
$11,880 | — | — |
| Ozempic |
|
$6,534 | 41 | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 15 in the dashboard with a free accountRecords
1,122 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in Texas
Ramin Farzaneh-Far
Cardiovascular Disease · Dallas, TX
Darren McGuire
Cardiovascular Disease · Dallas, TX
Peter McCullough
Cardiovascular Disease · Dallas, TX
Ann Navar
Cardiovascular Disease · Dallas, TX
Biykem Bozkurt
Cardiovascular Disease · Houston, TX
Milton Packer
Cardiovascular Disease · Dallas, TX
Related records
Cardiovascular Disease in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.